Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Microsoft Co. stock logo
MSFT
Microsoft
$392.85
+0.9%
$414.18
$303.40
$430.82
$2.92T0.8921.94 million shs2.31 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.72
+4.3%
$26.88
$25.20
$40.37
$151.30B0.6141.61 million shs14.98 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Microsoft Co. stock logo
MSFT
Microsoft
-3.21%-4.48%-7.46%-2.08%+27.42%
Pfizer Inc. stock logo
PFE
Pfizer
-0.16%-2.70%-7.71%-5.36%-34.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Microsoft Co. stock logo
MSFT
Microsoft
4.8767 of 5 stars
3.53.03.32.92.62.52.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9777 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Microsoft Co. stock logo
MSFT
Microsoft
2.94
Moderate Buy$452.6115.21% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3335.98% Upside

Current Analyst Ratings

Latest PFE and MSFT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$480.00 ➝ $500.00
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$450.00 ➝ $480.00
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$500.00
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$455.00 ➝ $465.00
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$465.00 ➝ $489.00
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$440.00 ➝ $470.00
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$475.00 ➝ $485.00
4/26/2024
Microsoft Co. stock logo
MSFT
Microsoft
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$450.00 ➝ $515.00
4/22/2024
Microsoft Co. stock logo
MSFT
Microsoft
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$455.00 ➝ $455.00
4/18/2024
Microsoft Co. stock logo
MSFT
Microsoft
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$480.00 ➝ $475.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Microsoft Co. stock logo
MSFT
Microsoft
$236.58B12.34$11.46 per share34.29$34.06 per share11.53
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.59$3.10 per share8.61$15.81 per share1.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Microsoft Co. stock logo
MSFT
Microsoft
$72.36B$11.5534.0129.762.1336.43%37.54%19.02%7/23/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3674.229.651.163.62%10.88%4.91%5/1/2024 (Confirmed)

Latest PFE and MSFT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57$0.82+$0.25N/A$13.87 billion$14.88 billion  
4/25/2024Q3 2024
Microsoft Co. stock logo
MSFT
Microsoft
$2.81$2.94+$0.13$2.94$60.86 billion$61.86 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Microsoft Co. stock logo
MSFT
Microsoft
$3.000.76%+10.11%25.97%22 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.29%+2.57%466.67%15 Years

Latest PFE and MSFT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
3/12/2024
Microsoft Co. stock logo
MSFT
Microsoft
quarterly$0.750.72%5/15/20245/16/20246/13/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Microsoft Co. stock logo
MSFT
Microsoft
0.17
1.24
1.23
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Microsoft Co. stock logo
MSFT
Microsoft
71.13%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Microsoft Co. stock logo
MSFT
Microsoft
0.03%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Microsoft Co. stock logo
MSFT
Microsoft
221,0007.43 billion7.43 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE and MSFT Headlines

SourceHeadline
Pfizer (NYSE:PFE) Releases FY24 Earnings GuidancePfizer (NYSE:PFE) Releases FY24 Earnings Guidance
marketbeat.com - May 1 at 9:35 AM
Pfizer (PFE) Q1 Earnings and Revenues Beat EstimatesPfizer (PFE) Q1 Earnings and Revenues Beat Estimates
zacks.com - May 1 at 8:55 AM
Pekin Hardy Strauss Inc. Sells 37,458 Shares of Pfizer Inc. (NYSE:PFE)Pekin Hardy Strauss Inc. Sells 37,458 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 1 at 8:46 AM
Pfizer revenues fall 19% due to lower COVID-related product demandPfizer revenues fall 19% due to lower COVID-related product demand
proactiveinvestors.com - May 1 at 8:14 AM
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid salesPfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
cnbc.com - May 1 at 7:13 AM
Amazon, Pfizer And 3 Stocks To Watch Heading Into WednesdayAmazon, Pfizer And 3 Stocks To Watch Heading Into Wednesday
benzinga.com - May 1 at 7:01 AM
Pfizer Q1 earnings: non-Covid product sales help post revenues of  $14.9 billion despite Comirnaty, Paxlovid declinePfizer Q1 earnings: non-Covid product sales help post revenues of  $14.9 billion despite Comirnaty, Paxlovid decline
invezz.com - May 1 at 7:01 AM
Pfizer beats profit estimates on cost cuts, RSV vaccine salesPfizer beats profit estimates on cost cuts, RSV vaccine sales
reuters.com - May 1 at 6:50 AM
Pfizer (NYSE:PFE) Trading 0.4% Higher Pfizer (NYSE:PFE) Trading 0.4% Higher
marketbeat.com - April 30 at 3:37 PM
Pfizer and Genmab Receive FDA Approval for Cervical Cancer DrugPfizer and Genmab Receive FDA Approval for Cervical Cancer Drug
baystreet.ca - April 30 at 2:54 PM
Pfizer Q1 Earnings Preview: Covid assets to remain the focus this quarterPfizer Q1 Earnings Preview: Covid assets to remain the focus this quarter
msn.com - April 30 at 2:54 PM
7 Safe Haven Stocks That Can Withstand the Markets Worst Meltdowns7 Safe Haven Stocks That Can Withstand the Market's Worst Meltdowns
investorplace.com - April 30 at 1:50 PM
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
zacks.com - April 30 at 12:21 PM
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 EarningsPfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
benzinga.com - April 30 at 12:01 PM
FDA approves Labcorp companion diagnostic for Pfizer gene therapyFDA approves Labcorp companion diagnostic for Pfizer gene therapy
finance.yahoo.com - April 30 at 9:54 AM
5 Top Stocks to Buy in May5 Top Stocks to Buy in May
fool.com - April 30 at 7:45 AM
Why Im Buying This Beaten-Down, High-Yield Dividend Stock Hand Over FistWhy I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
fool.com - April 30 at 5:50 AM
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks InsteadForget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks Instead
fool.com - April 30 at 5:06 AM
Pfizer Showcases Advancements in Breakthrough Cancer Treatments at ASCO 2024 Annual MeetingPfizer Showcases Advancements in Breakthrough Cancer Treatments at ASCO 2024 Annual Meeting
indiaeducationdiary.in - April 30 at 4:53 AM
Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1?Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1?
seekingalpha.com - April 30 at 4:53 AM
Pfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical CancerPfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical Cancer
markets.businessinsider.com - April 29 at 11:47 PM
Van ECK Associates Corp Raises Position in Pfizer Inc. (NYSE:PFE)Van ECK Associates Corp Raises Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 29 at 8:49 PM
These 3 High-Yield Stocks Have Been Growing Their Dividends Non-Stop, And Analysts Expect Their Share Prices To ClimbThese 3 High-Yield Stocks Have Been Growing Their Dividends Non-Stop, And Analysts Expect Their Share Prices To Climb
finance.yahoo.com - April 29 at 6:46 PM
UPDATE 1-US FDA grants full approval for Pfizers cervical cancer drugUPDATE 1-US FDA grants full approval for Pfizer's cervical cancer drug
finance.yahoo.com - April 29 at 6:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Microsoft logo

Microsoft

NASDAQ:MSFT
Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.